TNBC is a heterogeneous subtype of breast cancer, and only a subset of TNBC can be established as PDXs. Here, we show that there is an engraftment bias toward TNBC with low levels of immune cell infiltration. Additionally, TNBC that failed to engraft sho
FDA Grants Accelerated Approval to Tucatinib Combination for Patients with HER2-Positive Metastatic Colorectal Cancer Erin Hunter, Assistant Editor January 20th 2023 This is the first indication for tucatinib that extends beyond the treatment of advanced unresectable or metastatic HER2-positive breast cancer...
2. Current landscape of therapeutic vaccines for breast cancer 3. Vaccines targeting HER2 in breast cancer 4. Vaccines targeting triple-negative breast cancer 5. Vaccines targeting HR-positive breast cancer 6. Vaccines targeting breast cancer irrespective of the biological subtype 7. Other targets for...
S.D. reports institutional fees and non-financial support from Roche/Genentech; grants, institutional fees and nonfinancial support from Pfizer; institutional fees and nonfinancial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and no...
We have demonstrated for the first time that suppression of miRNA-221/222 increases the sensitivity of ER-positive MCF-7 breast cancer cells to tamoxifen. This effect is mediated through upregulation of TIMP3. These findings suggest that upregulation of TIMP3 via inhibition of miRNA-221/222 ...
Dr Chelmow reported serving as chair of the American College of Obstetricians and Gynecologists Practice Advisory Committee; in this role, he was involved in the development of practice guidelines related to breast cancer screening. Dr Barry reported receiving grants from Healthwise, a nonprofit, out...
AstraZeneca and Daiichi Sankyo have received the US FDA priority review for the application of breast cancer drug, trastuzumab deruxtecan.
As data continue to unfold with antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors in HER2positive breast cancer in earlier and curative settings, it will be particularly important to pay attention to treatment sequencing recommendations made by the National Comprehensive ...
The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence after chemotherapy and radiotherapy. Targeting BCSCs may ameliorate breast cancer relapse and therapy resistance. Here we report that expressi
The interplay of positive and negative interactions between drug-sensitive and resistant cells influences the effectiveness of treatment in heterogeneous cancer cell populations. Here, we study interactions between estrogen receptor-positive breast cancer cell lineages that are sensitive and resistant to ribo...